Myriad Genetics Q2 Revenue Falls Short by $15.3M as Cash Burn Accelerates
MYGN is trading near its 52-week low of $3.53 (5.2% below the low).
Summary
Myriad Genetics' Q2 2026 results missed revenue estimates by $15.3M, pressured by declining reimbursement and prior-period adjustments. Cash burn accelerated, and new equity plans signal potential dilution ahead.
Key Events · Earnings and Guidance · MYGN
-
Q2 Revenue Miss and Decline
Revenue of $190.7M missed consensus by $15.3M, down 11% YoY. An $11M reduction from prior-period collection estimates worsened the decline, reflecting deteriorating reimbursement trends.
-
Operating Loss and Cash Burn
Operating loss of $38.9M contributed to a net loss of $43.2M. Cash and equivalents fell to $115.2M from $149.6M at year-end 2025, with $24M used in operations during H1 2026.
-
Goodwill Impairment
A $4.5M goodwill impairment was recognized in Q1 2026 for the Women's Health reporting unit, reducing its carrying value to zero. Remaining goodwill of $47.1M is concentrated in Mental Health and International units.
-
New Equity Plans Authorized
Shareholders approved the 2026 Equity Incentive Plan (8.5M shares) and an amended Employee Stock Purchase Plan (4.0M additional shares). Combined with shares from the prior plan, up to 17.2M shares could be issued, representing significant potential dilution.
Analysis · MYGN · Life Sciences
Second-quarter revenue came in at $190.7 million, missing consensus by $15.3 million and declining 11% year-over-year. The shortfall was compounded by an $11 million reduction tied to prior-period collection estimates, pointing to worsening reimbursement trends. Operating losses widened to $38.9 million, and cash reserves dropped to $115.2 million from $149.6 million at year-end, raising concerns about the company's runway. A $4.5 million goodwill impairment in the Women's Health unit was also disclosed, alongside new equity plans that could introduce significant dilution. Set against a recent guidance cut and a suspended EBITDA outlook, these results paint a deteriorating financial picture.
At the time of this filing, MYGN was trading at $3.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $507.2M. The 52-week trading range was $3.53 to $8.59. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.